Wikiwand AI

Elecoglipron

Investigational drug From Wikipedia, the free encyclopedia

Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders. It is a glucagon-like peptide-1 receptor agonist. [1][2][3]

Other namesAZD-5004; ECC-5004
CAS Number
Quick facts Clinical data, Other names ...
Elecoglipron
Clinical data
Other namesAZD-5004; ECC-5004
Identifiers
  • 3-[1-[2-[(4S)-2-(3-cyclopropyl-4-fluorophenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]-7-[(4S)-2,2-dimethyloxan-4-yl]indolizin-3-yl]cyclopropyl]-4H-1,2,4-oxadiazol-5-one
CAS Number
PubChem CID
IUPHAR/BPS
UNII
KEGG
Chemical and physical data
FormulaC48H46F2N10O5
Molar mass880.958 g·mol−1
3D model (JSmol)
  • C[C@H]1C2=C(N(N=C2CCN1C(=O)C3=C(N4C=CC(=CC4=C3)[C@H]5CCOC(C5)(C)C)C6(CC6)C7=NOC(=O)N7)C8=CC(=C(C=C8)F)C9CC9)N1C=CN(C1=O)C1=C(C2=C(C=C1)N(N=C2)C)F
  • InChI=InChI=1S/C48H46F2N10O5/c1-26-39-36(53-60(30-7-8-35(49)32(22-30)27-5-6-27)42(39)59-19-18-58(46(59)63)38-10-9-37-34(40(38)50)25-51-55(37)4)12-17-56(26)43(61)33-23-31-21-28(29-13-20-64-47(2,3)24-29)11-16-57(31)41(33)48(14-15-48)44-52-45(62)65-54-44/h7-11,16,18-19,21-23,25-27,29H,5-6,12-15,17,20,24H2,1-4H3,(H,52,54,62)/t26-,29-/m0/s1
  • Key:JMKBTILBGROESC-WNJJXGMVSA-N
Close

References

Related Articles

Timelines

Top Qs

Fact Checks